344 related articles for article (PubMed ID: 19901933)
1. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
Freedland SJ; Eastham J; Shore N
Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Higano CS
Nat Clin Pract Urol; 2008 Jan; 5(1):24-34. PubMed ID: 18185511
[TBL] [Abstract][Full Text] [Related]
3. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
Ulloa EW; Salup R; Patterson SG; Jacobsen PB
Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer, osteoporosis and fracture risk.
Allain TJ
Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
6. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
Gomella LG
BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
8. Fracture risk in Danish men with prostate cancer: a nationwide register study.
Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
[TBL] [Abstract][Full Text] [Related]
9. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
10. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer.
Mottet N; Prayer-Galetti T; Hammerer P; Kattan MW; Tunn U
BJU Int; 2006 Jul; 98(1):20-7. PubMed ID: 16566812
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
12. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
[TBL] [Abstract][Full Text] [Related]
13. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
14. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
15. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
16. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
17. Managing complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM
Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
[TBL] [Abstract][Full Text] [Related]
18. Osteoporosis during androgen deprivation therapy for prostate cancer.
Smith MR
Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
[TBL] [Abstract][Full Text] [Related]
19. Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms.
Grunfeld EA; Halliday A; Martin P; Drudge-Coates L
Cancer Nurs; 2012; 35(1):63-9. PubMed ID: 21558849
[TBL] [Abstract][Full Text] [Related]
20. Pathologic effects of testosterone deprivation.
Sprenkle PC; Fisch H
Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]